electroCore Expands Intellectual Patent Portfolio for nVNS Technology
April 12, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...
electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan
April 11, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Teijin...
electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
April 06, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a...
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
April 04, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the...
electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023 16:05 ET
|
electroCore, Inc.
Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J.,...
National Headache Foundation Makes WorkMigraine Program Resources Free to the Public
January 05, 2023 15:18 ET
|
National Headache Foundation
Chicago, Illinois, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The National Headache Foundation (NHF) announced it is now making available free to the public its proven WorkMigraine program to help employers...
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022 07:28 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Neuromodulation Devices Market to Hit $14.16 Billion by 2030, Growing at a CAGR of 10.29%
September 05, 2022 08:40 ET
|
STRATEGIC MARKET RESEARCH LLP
New York, USA, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The Worldwide Neuromodulation Devices Market value was USD 6.10 Billion in 2021 and will reach USD 14.16 Billion in 2030 with a 10.29% CAGR....
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor
September 01, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Global Neuromodulation Market to Reach $4.3 Bn Globally, by 2030, at 6.2% CAGR: Says AMR
June 15, 2022 07:47 ET
|
Allied Market Research
Portland, OR, June 15, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Neuromodulation Market was estimated at $2.48 billion in 2020, and is...